These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15247556)

  • 1. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
    Lim ML; Min SS; Eron JJ; Bertz RJ; Robinson M; Gaedigk A; Kashuba AD
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1034-40. PubMed ID: 15247556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
    Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
    Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
    Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
    González de Requena D; Blanco F; Garcia-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2003 Sep; 17(9):443-5. PubMed ID: 14588081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
    Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
    Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
    Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
    J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
    la Porte CJ; Colbers EP; Bertz R; Voncken DS; Wikstrom K; Boeree MJ; Koopmans PP; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2004 May; 48(5):1553-60. PubMed ID: 15105105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
    Patterson KB; Dumond JB; Prince HA; Jenkins AJ; Scarsi KK; Wang R; Malone S; Hudgens MG; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 May; 63(1):51-8. PubMed ID: 23221983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.